Clinical Trials Browser

Aortic aneurysm, familial thoracic 4, Leukemia, Erythroblastic, Acute, Leukemia, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT02984995 2020-02-17

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Phase 2 Completed

37 enrolled 24 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01565668 2019-12-27

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2 Completed

76 enrolled 17 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT00989261 2019-12-11

ACE

Phase 2 Completed

333 enrolled 23 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT01049893 2019-02-12

Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors

Phase 1 Completed

45 enrolled

Other solid neoplasm

Solid Tumors

NCT01390337 2019-02-12

A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

Phase 1 Completed

19 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01468467 2019-02-12

A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)

Phase 1 Completed

13 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Clinical Trials

VENP-A-QUI

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

QuANTUM-WILD

Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

QuANTUM-First

A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Q-SOC

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

ACE

Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors

A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)